Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-III
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 516 participants.
Also called NCT05141305
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 516 participants
- Sponsor
- Registry
-
NCT05141305
-
- Other papers using this trial's data
- Clinical benefit of tenecteplase despite failed recanalization in late-window ischemic stroke: a post hoc analysis of the TRACE-3 trial
- Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without Thrombectomy
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05141305. Randomized; single masking; primary purpose treatment. Start 2022-01-19 (actual); primary completion 2024-01-29 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-III
- Acronym
- TRACE III
- Condition
- Ischemic Stroke, Acute
- Intervention (Drug)
- tenecteplase (0.25 mg/kg, Max 25 mg)
- Intervention (Drug)
- standard medical treatment
- Lead sponsor
- Beijing Tiantan Hospital
Record details
- Record id
cardio:ct-nct05141305- Content hash
0e91bc5683a329424b112826502725fcf8adc7fe82a1432af4795b4385252c79